Overall, the current work strongly suggests that the tetrapeptide EEAK may be a promising compound as a natural inhibitor of xanthine oxidase for the control of gout and hyperuricaemia (Yu et al., 2021). The gene discussed is XDH; the disease is hyperuricemia.